H.R. 1349

119 HR 1349 IH: Women’s Protection in Telehealth Act
 U.S. House of Representatives
 2025-02-13
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 1349  IN THE HOUSE OF REPRESENTATIVES   February 13, 2025   Mr. Steube  (for himself,  Ms. Tenney ,  Mr. Haridopolos ,  Mr. McGuire , and  Mr. Biggs of Arizona ) introduced the following bill; which was referred to the  Committee on Ways and Means , and in addition to the Committee on  Energy and Commerce , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned   A BILL
To amend title XI of the Social Security Act to exclude providers of certain abortion services from participation in the Medicare program.
1.
Short title
This Act may be cited as the   Women’s Protection in Telehealth Act  .
2.
Excluding providers of certain abortion services from participation in the Medicare program
Section 1128 of the Social Security Act ( 42 U.S.C. 1320a–7 ) is amended—
(1)
in subsection (a)—
(A)
in the matter preceding paragraph (1), by inserting  (or, in the case of individuals and entities described in paragraph (5), from participation in the Medicare program under title XVIII)  after  (as defined in section 1128B(f)) ; and
(B)
by inserting after paragraph (4) the following new paragraph:
(5)
Provision of abortion-inducing drugs
Any individual or entity that, on or after the date of the enactment of this paragraph, prescribes, administers, dispenses, or furnishes an abortion-inducing drug to a patient, unless such individual or entity—
(A)
is a physician;
(B)
physically examines the patient;
(C)
is physically present in the same room with the patient at the time the patient is administered, takes, or uses (as applicable) such drug; and
(D)
schedules an in-person follow-up visit for the patient to occur not more than 14 days after the patient is administered, takes, or uses (as applicable) such drug.
 ; and
(2)
in subsection (c)(3)—
(A)
in subparagraph (A), by striking  subsection (b)(12)  and inserting  subsection (a)(5) or (b)(12) ;
(B)
in subparagraph (B), by striking  subparagraph (G)  and inserting  subparagraphs (G) and (H) ;
(C)
in subparagraph (G), by inserting  (other than under paragraph (5) of such subsection)  after  subsection (a) ; and
(D)
by adding at the end the following new subparagraph:
(H)
In the case of an exclusion under subsection (a)(5), the exclusion shall be permanent.
 ;
(3)
in subsection (d), by adding at the end the following new paragraph:
(4)
The provisions of this subsection shall not apply in the case of an exclusion under subsection (a)(5).
 ;
(4)
in subsection (g), by adding at the end the following new paragraph:
(4)
The provisions of this subsection shall not apply in the case of an exclusion under subsection (a)(5).
 ; and
(5)
by adding at the end the following new subsection:
(k)
Abortion-Inducing drug defined
(1)
In general
For purposes of subsection (a), the term  abortion-inducing drug  means any medicine, drug, or any other substance that is prescribed, administered, dispensed, or furnished with the intent of terminating the clinically diagnosable pregnancy of a woman and with knowledge that the termination will with reasonable likelihood cause the death of the unborn child (including the off-label use of any such drug).
(2)
Unborn child
The term  unborn child  has the meaning given such term in section 1841 of title 18, United States Code.
 .